A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )
ClinicalTrials.gov Identifier:
NCT01119651
First received: May 5, 2010
Last updated: April 19, 2012
Last verified: April 2012

May 5, 2010
April 19, 2012
June 2010
June 2010   (final data collection date for primary outcome measure)
Inflammatory skin responses [ Time Frame: 54 days ] [ Designated as safety issue: No ]
Patch site evaluations for signs of inflammatory skin responses and superficial effect
Same as current
Complete list of historical versions of study NCT01119651 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.
A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers

The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.

This is a Phase 1, single center, evaluator-blinded, randomized, vehicle controlled study to evaluate the potential of tazarotene foam 0.1% to induce a photoallergic reaction in healthy adult volunteers. Approximately 62 healthy, male and female, volunteer subjects aged 18 to 65 years will be enrolled.

All subjects will be exposed to patches containing tazarotene foam, vehicle foam, and no foam (blank; negative control). Inflammatory skin responses (eg, erythema and local skin reactions) or superficial effects at patch sites will be visually assessed to corresponding grading scales. The study duration will be 6 weeks or 9 weeks and will consist of the following phases: Screening, 3 week Induction, 2 week Rest, and 1 week Challenge, and if indicated, a second 2 week Rest and 1 week Repeat Challenge.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Basic Science
Acne Vulgaris
Drug: Tazarotene (Patch application in Challenge Phase)
There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated & will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
  • Experimental: Tazarotene Foam without irradiation
    Subjects will be exposed to Tazarotene Foam Patch without irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Experimental: Tazarotene Foam with UVA and UVB irradiation
    Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Experimental: Tazarotene Foam & UVA/UVB/visible light
    Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Placebo Comparator: Vehicle Foam without irradiation,
    Subjects will be exposed to Vehicle Foam Patch without irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Placebo Comparator: Vehicle Foam with UVA and UVB irradiation
    Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Placebo Comparator: Vehicle Foam with UVA & UVB visible light irradiation
    Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Sham Comparator: Blank patch without irradiation
    Subjects will be exposed to blank patch without irradiation,
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Sham Comparator: Blank patch with UVA and UVB irradiation
    Subjects will be exposed to blank patch with UVA and UVB irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
  • Sham Comparator: Blank Patch with UVA & UVB visible light irradiation
    Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
    Intervention: Drug: Tazarotene (Patch application in Challenge Phase)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
September 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Capable of understanding and willing to provide signed and dated written voluntary informed consent and Health Information Portability and Accountability Act (HIPAA) authorization before any protocol-specific procedures are performed.
  • Male or female aged 18 to 65 years, inclusive, at time of consent.
  • Able and willing to complete the study and to comply with all study instructions.
  • Possess Fitzpatrick skin types I (always burns easily; never tans), II (always burns easily; tans minimally), or III (burns moderately; tans gradually) that will not interfere with the evaluation of any skin responses (Fitzpatrick 1988). Determination of skin types will be based on sunburn and tanning histories, as well as subjects' opinions of their responses to the first 30 to 45 minutes of sun exposure.
  • Male subjects and their partners must agree to use a medically acceptable method of contraception.

Additional criteria for women of childbearing potential, defined as one who is biologically capable of becoming pregnant, including perimenopausal women who are less than 2 years from their last menses:

  • A regular menstrual cycle before study entry (as reported by the subject).
  • Negative urine pregnancy test within 2 weeks of the first application of study product.
  • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception throughout the duration of the study. Acceptable contraceptive methods include the following:

    • Hormonal contraception, including oral, injectable, or implantable methods started at least 2 months prior to screening. If hormonal contraception was started less than 2 months prior to screening, then a form of nonhormonal contraception should be added until the third continuous month of hormonal contraception has been completed.
    • Two forms of reliable nonhormonal contraception, to include the use of either an intrauterine device plus a reliable barrier method or 2 reliable barrier methods. Reliable barrier methods include condoms or diaphragms. A cervical cap is also a reliable barrier method, provided that the female subject has never given birth vaginally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Subjects with surgical sterilization, including tubal sterilization or partner's vasectomy, must use a form of nonhormonal contraception. A barrier method or sterilization plus spermicide is acceptable.

Women who are not currently sexually active must agree to use a medically acceptable method of contraception should they become sexually active while participating in the study

Exclusion Criteria:

  • Female who is pregnant, trying to become pregnant, or breast feeding.
  • Considered unable or unlikely to attend the necessary visits.
  • History of known or suspected intolerance to tazarotene, any of the ingredients of the study products, the hypoallergenic tape, or the cotton patches.
  • Participation in any patch test study within 4 weeks of Screening Visit 1.
  • Inability to evaluate the skin in and around the potential patch test sites on the back due to sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality.
  • Clinically significant skin diseases that may contraindicate participation or interfere with patch test site evaluations, including psoriasis, eczema, atopic dermatitis, acne, dysplastic nevi, or other skin pathologies, or a history of skin cancer.
  • A history of severe reactions from exposure to sunlight, including previous experience with photoallergy, solar urticaria, polymorphous light eruptions, or other photo exacerbated systemic diseases.
  • Any major illness within 4 weeks of Screening Visit 1.
  • Considered immunocompromised.
  • A clinically relevant history of or current evidence of abuse of alcohol or other drugs.
  • Clinically relevant history or currently suffering from any disease or condition that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk. This may include respiratory (including chronic asthma requiring repetitive drug interventions), gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
  • Used photosensitizing medications (prescription, nonprescription, or herbal) or a known photosensitizing material within 2 weeks of Screening Visit 1.
  • Received any investigational product or procedure within 4 weeks of Screening Visit 1 or is scheduled to receive an investigational product (other than the study product) or procedure during the study.
  • Received allergy injections within 1 week of Screening Visit 1, or expects to receive allergy injections during study participation.
  • Received immunizations within 4 weeks of Screening Visit 1.
  • Used systemic or topical corticosteroids or other immunosuppressive medications within 4 weeks of Screening Visit 1.
  • Used topical medications or other products (eg, self tanning products, waxing products, benzoyl peroxide, salicylic acid, or sulfur) in the areas of patch testing within 2 weeks of Screening Visit 1.
  • Used antihistamines, selective leukotriene receptor antagonists (eg, montelukast sodium, zafirlukast), or mast cell stabilizers (eg, cromolyn sodium or nedocromil sodium) within 4 weeks of Screening Visit 1.
  • Used nonsteroidal anti inflammatory medications within 2 weeks of Screening Visit 1.
  • Currently using any medication that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.
  • Participated in a previous study of the same study product.
  • Employee of the study center, contract research organization, or Stiefel who is involved in the study, or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee who is involved in the study.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01119651
114574, W0260-104
No
GlaxoSmithKline ( Stiefel, a GSK Company )
Stiefel, a GSK Company
GlaxoSmithKline
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP